Interestingly, using our in-house bladder UC tissue samples (n = 79), we showed that compared with the benign tissue samples, MED10 expression, alongside Ki67, OCT4, and LIN28A, is disease progression from non-muscle invasive bladder cancer (NMIBC: pT1) to muscle-invasive bladder cancer (MIBC: pT2–pT4) and more so in patients with distant metastatic disease (M1) (benign < T1 < T2 < T3/4 < M1) (Figure 7B). Here, MED10 is linked to metastatic neoplasm.